Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223

Overall survival prediction in metastatic castration-resistant prostate cancer treated with radium-223

ABSTRACT Objective Radium-223(223Ra) is indicated for patients (p) with metastatic castration resistant prostate cancer (mCRCP). Objectives The aim of this study was to evaluate the role of baseline clinical variables associated with overall survival (OS) and toxicity of 223Ra. Its purpose was t...

Full description

Bibliographic Details
Main Authors:	Monica Vidal, Alejandro Delgado, Carlos Martinez, José Jaime Correa, Isabel Cristina Durango
Format:	Article
Language:	English
Published:	Sociedade Brasileira de Urologia
Series:	International Brazilian Journal of Urology
Subjects:	radium-223 [supplementary concept] castration prostatic neoplasms
Online Access:	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1677-55382020000400599&lng=en&tlng=en

Similar Items

RADIUM-223. PLACE IN THE TREATMENT OF METASTATIC CASTRATION-REFRACTORY PROSTATE CANCER
by: A. A. Kostin, et al.
Published: (2017-12-01)

Optimal usage of radium-223 in metastatic castration-resistant prostate cancer
by: Tai-Lung Cha, et al.
Published: (2017-11-01)

Radium-223 in metastatic castration resistant prostate cancer
by: Winston Vuong, et al.
Published: (2014-06-01)

Pain predicts overall survival in men with metastatic castration-resistant prostate cancer treated with radium-223
by: Roviello G, et al.
Published: (2018-12-01)

Еfficiacy and safety of radium-223 in the treatment of metastatic castration-resistant prostate cancer
by: I. G. Rusakov, et al.
Published: (2020-12-01)

POSSIBILITIES OF RADIUM-223 APPLICATION IN THERAPY OF PROSTATE GLAND CANCER
by: A. A. GRITSKEVICH, et al.
Published: (2017-06-01)

Radium-223 in treatment of castration-resistant prostate cancer with skeletal metastases
by: V. B. Matveev, et al.
Published: (2017-10-01)

Radium-223 for the treatment of patients with castration-resistant prostate cancer with bone metastases
by: A. D. Kaprin, et al.
Published: (2018-07-01)

Histopathology of castration-resistant prostate cancer confirms changes in bone metastasis during radium-223 treatment: A case report
by: Masato Dobashi, et al.
Published: (2020-09-01)

Radium-223 Treatment of Patients with Metastatic Castration Resistant Prostate Cancer: Biomarkers for Stratification and Response Evaluation
by: Kim van der Zande, et al.
Published: (2021-08-01)

Radium chloride [223Ra] for patients with prostate cancer and skeletal metastases. Clinical recommendations
by: T Yu. Kochetova, et al.
Published: (2020-04-01)

Radium 223 dichloride for prostate cancer treatment
by: Deshayes E, et al.
Published: (2017-09-01)

Immunophenotyping Reveals Longitudinal Changes in Circulating Immune Cells During Radium-223 Therapy in Patients With Metastatic Castration-Resistant Prostate Cancer
by: Jeroen H. A. Creemers, et al.
Published: (2021-05-01)

Can bone scans guide therapy with radium-223 dichloride for prostate cancer bone metastases?
by: Gayed I, et al.
Published: (2018-09-01)

Alpha-therapy using radium-223 chloride in patients with castration-resistant prostate cancer. From clinical researches to routine practice
by: K. M. Nyushko, et al.
Published: (2020-01-01)

Radium-223 systemic alpha-radiotherapy: targeted treatment of castration-resistant prostate cancer with bone metastases
by: М. I. Volkova, et al.
Published: (2019-07-01)

Quantifying the survival benefit of completing all the six cycles of radium-223 therapy in patients with castrate-resistant prostate cancer with predominant bone metastases
by: John Buscombe, et al.
Published: (2021-01-01)

Efficacy and safety of radium-223 in routine clinical practice
by: V. B. Matveev, et al.
Published: (2021-02-01)

Radium-223-Dichloride in Castration Resistant Metastatic Prostate Cancer—Preliminary Results of the Response Evaluation Using F-18-Fluoride PET/CT
by: Kalevi Kairemo, et al.
Published: (2015-10-01)

Dynamic changes of bone metastasis predict bone‐predominant status to benefit from radium‐223 dichloride for patients with castration‐resistant prostate cancer
by: Kohei Hashimoto, et al.
Published: (2020-11-01)

Prognostic Value of <sup>18</sup>F-Choline PET/CT in Patients with Metastatic Castration-Resistant Prostate Cancer Treated with Radium-223
by: Luca Filippi, et al.
Published: (2020-11-01)

Population-Based Analysis Of The Use Of Radium-223 For Bone-Metastatic Castration-Resistant Prostate Cancer In Ontario, And Of Factors Associated With Treatment Completion And Outcome
by: Cheng S, et al.
Published: (2019-10-01)

Treatment sequencing in metastatic castrate-resistant prostate cancer
by: Oliver Sartor, et al.
Published: (2014-06-01)

SEQUENTIAL THERAPY OF METASTATIC CASTRATION-RESISTANT PROSTATE CANCER: NEW POSSIBILITIES
by: A. S. Markova, et al.
Published: (2018-10-01)

The Prognostic Role of Baseline Metabolic Tumor Burden and Systemic Inflammation Biomarkers in Metastatic Castration-Resistant Prostate Cancer Patients Treated with Radium-223: A Proof of Concept Study
by: Matteo Bauckneht, et al.
Published: (2020-10-01)

Radium-223 in asymptomatic patients with castration-resistant prostate cancer and bone metastases treated in an international early access program
by: Axel Heidenreich, et al.
Published: (2019-01-01)

uPAR PET/CT for Prognostication and Response Assessment in Patients with Metastatic Castration-Resistant Prostate Cancer Undergoing Radium-223 Therapy: A Prospective Phase II Study
by: Marie Øbro Fosbøl, et al.
Published: (2021-06-01)

Metastatic castration-resistant prostate cancer and the challenge of a patient with chronic kidney disease in hemodialysis
by: Joana Simões, et al.
Published: (2018-06-01)

Combinatorial effect of radium-223 and irreversible electroporation on prostate cancer bone metastasis in mice
by: Raniv D. Rojo, et al.
Published: (2021-01-01)

Radionuclide therapy with radium-223 chloride. A few strokes to the patient’s portrait
by: V. N. Oschepkov, et al.
Published: (2019-01-01)

A phase II randomized trial of RAdium-223 dichloride and SABR Versus SABR for oligomEtastatic prostate caNcerS (RAVENS)
by: Hamza Hasan, et al.
Published: (2020-06-01)

An agent-based model of prostate Cancer bone metastasis progression and response to Radium223
by: Stefano Casarin, et al.
Published: (2020-06-01)

Trastuzumab Modified Barium Ferrite Magnetic Nanoparticles Labeled with Radium-223: A New Potential Radiobioconjugate for Alpha Radioimmunotherapy
by: Weronika Gawęda, et al.
Published: (2020-10-01)

The Mode-of-Action of Targeted Alpha Therapy Radium-223 as an Enabler for Novel Combinations to Treat Patients with Bone Metastasis
by: Mari I. Suominen, et al.
Published: (2019-08-01)

Can radium 223 be a conservative non-surgical management of medication-related osteonecrosis of the jaw?
by: Renato Patrizio Costa, et al.
Published: (2019-01-01)

Bone pain palliation outcomes and possibility of Radium-223 re-treatment in mCRPC
by: Viviana Frantellizzi, et al.
Published: (2020-10-01)

Additive Benefits of Radium-223 Dichloride and Bortezomib Combination in a Systemic Multiple Myeloma Mouse Model
by: Mari I. Suominen, et al.
Published: (2021-05-01)

Radioisotopes in management of metastatic prostate cancer
by: Amar Raval, et al.
Published: (2016-01-01)

Retrospective Toxicological Profiling of Radium-223 Dichloride for the Treatment of Bone Metastases in Prostate Cancer Using Adverse Event Data
by: Theodoros G. Soldatos, et al.
Published: (2019-05-01)

Quantitative measurement of 219Rn radioactivity in exhaled breath from patients with bone metastasis of castration-resistant prostate cancer treated with 223RaCl2
by: Kazuhiro Ooe, et al.
Published: (2019-07-01)

Cannot write session to /tmp/vufind_sessions/sess_euar75d8nkk7notj2o8ihiu0tp